Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer

Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer

Purpose Immune checkpoint inhibition (ICI) therapy has improved patient outcomes in advanced non-small cell lung cancer (NSCLC), but better biomarkers are needed. A clinically validated, blood-based proteomic test, or host immune classifier (HIC), was assessed for its ability to predict ICI therapy...

Full description

Saved in:
Bibliographic Details
Main Authors: Wallace Akerley, Ray Page, Paul R Walker, Jonathan Goldberg, Jason Boyd, Patricia Rich, R Brian Mitchell, Eric Schaefer, John W Dubay, David Oubre, Mazen Khalil, Suman Sinha, Scott Boniol, Hafez Halawani, Edgardo S Santos, Warren Brenner, James M Orsini, Emily Pauli, Andrea Veatch, Mitchell Haut, Bassam Ghabach, Savita Bidyasar, Maria Quejada, Waseemullah Khan, Kan Huang, Linda Traylor
Format: Article
Language:English
Published: BMJ Publishing Group 2021-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/10/e002989.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/9/10/e002989.full

Similar Items